Metoclopramide Basi

Metoclopramide Hydrochloride Monohydrate, the active ingredient in Metoclopramide Basi, is a dopamine D2 receptor antagonist presented as an injectable solution for intramuscular and intravenous use. It is employed to control nausea and vomiting and to enhance gastrointestinal motility in adult patients. GNH USA supplies Metoclopramide Basi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Metoclopramide is an anti‑emetic that acts on the chemoreceptor trigger zone and gastrointestinal tract. - Nausea and vomiting (including postoperative and chemotherapy‑induced): reduces the frequency and severity of episodes. - Gastroparesis: accelerates gastric emptying and improves related symptoms. - Migraine-associated nausea: alleviates nausea accompanying migraine attacks. - Diagnostic procedures requiring gastric emptying: facilitates timely completion of studies.

Metoclopramide may cause a range of adverse reactions.

Common Side Effects: - Drowsiness or fatigue. - Restlessness or akathisia. - Dry mouth. - Diarrhea or abdominal cramping. - Headache. - Dizziness.

Serious or Rare Side Effects: - Tardive dyskinesia (involuntary movements). - Extrapyramidal symptoms (e.g., dystonia, parkinsonism). - Neuroleptic malignant syndrome. - Severe allergic reactions (anaphylaxis, skin rash). - Depression or suicidal ideation. - Seizures.

Metoclopramide requires careful monitoring in several clinical situations. - Extrapyramidal monitoring: watch for muscle rigidity, tremor, or abnormal movements. - Depression risk: assess for mood changes, especially in patients with a history of depression. - Parkinson's disease: avoid use as it may worsen motor symptoms. - Renal impairment: dose adjustment may be needed in patients with reduced kidney function. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk. - Store at room temperature: keep in the original container, protect from moisture and light.

Metoclopramide can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other dopamine antagonists: additive extrapyramidal effects. - CNS depressants (e.g., benzodiazepines, opioids): enhanced sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Opioid analgesics: may increase risk of constipation and reduced gastric motility. - Anticholinergic agents: may diminish pro‑kinetic effect. - Serotonergic drugs (SSRIs, SNRIs, triptans): potential for serotonin syndrome. - Alcohol: may potentiate central nervous system depression.